Background/Aims: Vaginismus is characterized by recurrent or persistent involuntary contraction of the perineal muscles surrounding the outer third of the vagina when penile, finger, tampon, or speculum penetration is attempted. Recent results have suggested the use of botulinum toxin for the treatment of vaginismus. Here, we assessed previously published data to evaluate the therapeutic effectiveness of botulinum toxin for vaginismus. Methods: We have carried out a systematic review followed by a meta-analysis. Results: Our results indicate that botulinum toxin is an effective therapeutic option for patients with vaginismus (pooled odds ratio of 8.723 with 95% confidence interval limits of 1.942 and 39.162, p = 0.005). This may hold particularly true in treatment-refractory patients because most of the studies included in this meta-analysis have enrolled these subjects in their primary analysis. Conclusion: Botulinum toxin appears to be a reasonable intervention for vaginismus. However, this conclusion should be read carefully because of the deficiency of placebo-controlled randomized clinical trials and the quality issues presented in the existing ones.

Keywords:
Vaginismus, Botox, Botulinum toxin
1.
Crowley T, Richardson D, Goldmeier D: Recommendations for the management of vaginismus: BASHH Special Interest Group for Sexual Dysfunction. Int J STD AIDS 2006;17:14–18.
2.
Crowley T, Goldmeier D, Hiller J: Diagnosing and managing vaginismus. BMJ 2009;338:b2284.
3.
Abdo CH, Oliveira WM Jr, Moreira ED Jr, Fittipaldi JA: Prevalence of sexual dysfunctions and correlated conditions in a sample of Brazilian women – results of the Brazilian study on sexual behavior (BSSB). Int J Impot Res 2004;16:160–166.
4.
Lewis RW, Fugl-Meyer KS, Bosch R, Fugl-Meyer AR, Laumann EO, Lizza E, Martin-Morales A: Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004;1:35–39.
5.
Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, Rellini AH, Segraves T: Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 2010;7:1598–1607.
6.
Spector IP, Carey MP: Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav 1990;19:389–408.
7.
Dogan S: Vaginismus and accompanying sexual dysfunctions in a Turkish clinical sample. J Sex Med 2009;6:184–192.
8.
Kao A, Binik YM, Kapuscinski A, Khalife S: Dyspareunia in postmenopausal women: a critical review. Pain Res Manag 2008;13:243–254.
9.
McGuire H, Hawton K: Interventions for vaginismus. Cochrane Database Syst Rev 2003:CD001760.
10.
Brin MF, Vapnek JM: Treatment of vaginismus with botulinum toxin injections. Lancet 1997;349:252–253.
11.
Pacik PT: Vaginismus: review of current concepts and treatment using botox injections, bupivacaine injections, and progressive dilation with the patient under anesthesia. Aesthetic Plast Surg 2011;35:1160–1164.
12.
Burgen AS, Dickens F, Zatman LJ: The action of botulinum toxin on the neuromuscular junction. J Physiol 1949;109:10–24.
13.
Whittemore R, Knafl K: The integrative review: updated methodology. J Adv Nurs 2005;52:546–553.
14.
Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG: Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006;6:50.
15.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
16.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
17.
Sterne JA, Egger M: Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001;54:1046–1055.
18.
Shafik A, El-Sibai O: Vaginismus: results of treatment with botulin toxin. J Obstet Gynaecol 2000;20:300–302.
19.
Fageeh WM: Different treatment modalities for refractory vaginismus in western Saudi Arabia. J Sex Med 2011;8:1735–1739.
20.
Ghazizadeh S, Nikzad M: Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004;104:922–925.
21.
Pacik PT: Botox treatment for vaginismus. Plast Reconstr Surg 2009;124:455e–456e.
22.
Glass GV: Integrating findings: the meta-analysis of research. Rev Res Educ 1977;5:351–379.
23.
Park AJ, Paraiso MF: Successful use of botulinum toxin type a in the treatment of refractory postoperative dyspareunia. Obstet Gynecol 2009;114:484–487.
24.
Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG: Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006;108:915–923.
25.
Yoon H, Chung WS, Shim BS: Botulinum toxin A for the management of vulvodynia. Int J Impot Res 2007;19:84–87.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.